Asterias Biotherapeutics

Asterias Biotherapeutics initiates trial for complete cervical spinal cord injury

Thursday, March 5, 2015

Asterias Biotherapeutics, a biotechnology company in the emerging field of regenerative medicine, announced that Atlanta-based Shepherd Center, a rehabilitation hospital for spinal cord injury and brain injury, has commenced enrollment for the phase I/IIa clinical trial of AST-OPC1 (oligodendrocyte progenitor cells) in newly injured patients with sensory and motor complete cervical spinal cord injury (SCI).

[Read More]

Cancer Research U.K., Cancer Research Technology, Asterias Biotherapeutics partner

Friday, September 19, 2014

Cancer Research U.K. and Cancer Research Technology (CRT), the charity’s development and commercialization arm, have reached an agreement with Asterias Biotherapeutics, a California-based biotechnology company focused on regenerative medicine, to take forward Asterias’ novel immunotherapy treatment AST-VAC2 into clinical trials in subjects with non-small cell lung cancer.

[Read More]